FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 337:927-928 September 25, 1997 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Zanamivir, a new antiviral agent for influenza, is a potent inhibitor of the viral neuraminidase of types A and B influenzaviruses.¹ The design of zanamivir was based on the three-dimensional structure of the neuraminidase, a structural unit on the surface of the viral particle. In this issue of the Journal, Hayden et al. report that treatment of community-acquired type A and B influenza with zanamivir shortened the duration of major symptoms by about one day in the study group as a whole and about three days in the sicker patients if the drug was started early.² Zanamivir probably interrupts an . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Wright, P. (2000). Influenza in the Family. NEJM 343: 1331-1332 [Full Text]  
• Pica, F., Palamara, A. T., Rossi, A., De Marco, A., Amici, C., Santoro, M. G. (2000). Delta 12-Prostaglandin J2 Is a Potent Inhibitor of Influenza A Virus Replication. Antimicrob. Agents Chemother. 44: 200-204 [Abstract] [Full Text]  
• (1997). A New Agent Against the Flu. Journal Watch Dermatology 1997: 17-17 [Full Text]  
• (1997). A NEW AGENT AGAINST THE FLU. JWatch General 1997: 3-3 [Full Text]